uploads/2018/09/QURE-pipeline-1.png

uniQure: Its Promising Research Pipeline

By

Updated

Company overview

uniQure (QURE) is advancing a pipeline of gene therapies that are developed internally and externally. It has a collaboration with Bristol-Myers Squibb (BMY) that’s targeted at cardiovascular disease. uniQure has also established a clinical proof of concept in hemophilia B and pre-clinical proof of concept in Huntington’s disease.

uniQure’s AMT-061 is being developed for the treatment of hemophilia B. In June, the company enrolled the first patient in its Phase 3 study of AMT-061 to study the drug’s safety and efficacy. uniQure plans to enroll 50 patients in the study.

uniQure’s AMT-130 is being developed for the treatment of Huntington’s disease. AMT-130 has received orphan drug designation in the United States and orphan medicinal product designation from the European Medicines Agency.

Article continues below advertisement

Top line

uniQure generated total licensing and collaboration revenues of $3.05 million in the second quarter of 2018 compared to $4.94 million in Q2 2017. For fiscal 2018 and fiscal 2019, uniQure is expected to generate revenues of $15.06 million and $14.88 million, respectively, compared to $13.11 million in fiscal 2017.

uniQure’s research and development expenses increased from $16.87 million in the second quarter of 2017 to $18.49 million in the second quarter of 2018. It’s selling, general, and administrative expenses increased from $5.41 million in the second quarter of 2017 to $5.89 million in the second quarter of 2018.

We’ll take a look at uniQure’s valuation metrics in the next part.

Advertisement

More From Market Realist